Efficacy of Ustekinumab (Anti-IL-12/23) Followed by Abatacept (CTLA4-Ig) for the Treatment of Psoriasis Vulgaris(ITN059AI)
Phase of Trial: Phase II
Latest Information Update: 27 Dec 2018
Price : $35 *
At a glance
- Drugs Abatacept (Primary) ; Ustekinumab (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Acronyms PAUSE
- 20 Mar 2018 Status changed from active, no longer recruiting to completed.
- 08 Jan 2018 Planned End Date changed from 1 Mar 2018 to 12 Mar 2018.
- 19 Oct 2017 Planned End Date changed from 1 Feb 2018 to 1 Mar 2018.